New entrants (i.e., Mark Cuban Cost Plus Drugs), plus innovative models from disruptors (i.e., Amazon RxPass) will push continued reform of the drug purchasing and PBM landscape, while outcomes-based arrangements will be a dominant strategy among payers to help control drug spending, specifically on high cost, specialty medications.